Zoetis Inc (ZTS-N) Stock Predictions - Stockchase
WATCH LIST
9
Zoetis Inc (ZTS-N)

ON STOCKCHASE SINCE Jun 2013

Consumer Products

Zoetis Inc

ZTS-N

7 watching          
Join the Discussion

Zoetis Inc (ZTS-N) SAVE Nov, 16, 2018, 12:10 am

91.62 0.86 (0.93%)

About Zoetis Inc (ZTS-N)

Zoetis, Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of ... More at Wikipedia

What the experts are saying about ZTS-N



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Zoetis Inc(ZTS-N) 

November 7, 2018

Big producer of medicine and vaccines for livestock and pets, with revenues roughly evenly split between those two areas. Living standards are rising in developing countries, so they need vaccines for healthy livestock. Also, pet owners will pay well (vaccines) to heal their pets. (Analysts’ price target is $98.91)
Consumer Products
0 0 0 0 0
0 comments
Big producer of medicine and vaccines for livestock and pets, with revenues roughly evenly split between those two areas. Living standards are rising in developing countries, so they need vaccines for healthy livestock. Also, pet owners will pay well (vaccines) to heal their pets. (Analysts’ price target is $98.91)
Consumer Products
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$95.190
Owned Owned
Yes

TOP PICK
Zoetis Inc(ZTS-N) 

September 12, 2018

Animal health care involving drugs. Largest producer of medicine in the pet and livestock space. Spun off from Pfizer. Likes it because of minimal generic competition, and a fragmented customer base. A defensive growth name. Yield is 0.6%. (Analysts’ price target is $93.27.) 

Consumer Products
0 0 0 0 0
0 comments

Animal health care involving drugs. Largest producer of medicine in the pet and livestock space. Spun off from Pfizer. Likes it because of minimal generic competition, and a fragmented customer base. A defensive growth name. Yield is 0.6%. (Analysts’ price target is $93.27.) 

Consumer Products
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$88.240
Owned Owned
Yes

TOP PICK
Zoetis Inc(ZTS-N) 

August 20, 2018

Was spun out of Pfizer. They make pharma for livestock and pharma for companion animals. The latter is growing faster than the former. They bought out a competitor in diagnostics so they have a stronger share in that area, which is a rapidly growing market. He's done well with it ever since Clinton attacked big pharma. (0.6% dividend) (Analysts' price target: $93.27)

Consumer Products
0 0 0 0 0
0 comments

Was spun out of Pfizer. They make pharma for livestock and pharma for companion animals. The latter is growing faster than the former. They bought out a competitor in diagnostics so they have a stronger share in that area, which is a rapidly growing market. He's done well with it ever since Clinton attacked big pharma. (0.6% dividend) (Analysts' price target: $93.27)

Consumer Products
0 0 0 0 0
0 comments
David Fingold

VP and Por, Dynamic Funds...

Price Price
$91.470
Owned Owned
Yes

COMMENT
Zoetis Inc(ZTS-N) 

March 21, 2018

Fabulous stock. He took profits, but still likes this. Valuation has risen, currently at 27x earnings, which is why he exited.

Consumer Products
0 0 0 0 0
0 comments

Fabulous stock. He took profits, but still likes this. Valuation has risen, currently at 27x earnings, which is why he exited.

Consumer Products
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$84.100
Owned Owned
No

COMMENT
Zoetis Inc(ZTS-N) 

June 22, 2016

An animal health company that was spun out of Pfizer (PFE-N) in 2013. They have 2 lines of business. 1.) Vaccines and antibiotics for livestock including cattle, swine and poultry, in that order, for about 65% of their revenue. 2.) Antibiotics for companion animals. A great growth profile in emerging markets. Trading at about 25X PE this year, going down to about 20X with about 20% EPS growth. A well-run company. He could see more upside in this.

Consumer Products
0 0 0 0 0
0 comments

An animal health company that was spun out of Pfizer (PFE-N) in 2013. They have 2 lines of business. 1.) Vaccines and antibiotics for livestock including cattle, swine and poultry, in that order, for about 65% of their revenue. 2.) Antibiotics for companion animals. A great growth profile in emerging markets. Trading at about 25X PE this year, going down to about 20X with about 20% EPS growth. A well-run company. He could see more upside in this.

Consumer Products
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$47.330
Owned Owned
No

BUY
Zoetis Inc(ZTS-N) 

January 5, 2015

A very defensible business.  Has pricing power on most of its drug portfolio.  They have been under levered for a significant period of time.

Consumer Products
0 0 0 0 0
0 comments

A very defensible business.  Has pricing power on most of its drug portfolio.  They have been under levered for a significant period of time.

Consumer Products
0 0 0 0 0
0 comments
Peter Mann

Portfolio , Gluskin Scheff & Ass...

Price Price
$43.050
Owned Owned
Yes

PAST TOP PICK
Zoetis Inc(ZTS-N) 

November 13, 2014

(Top Pick Oct 30/13, Up 34.92%) This is a spin off from Pfizer and focused on animals.  Sales are growing at 3 times industry average because they dominate in market share.  1 of 3 FDA approved drugs are theirs.  They are looking to increase their operating efficiencies.

Consumer Products
0 0 0 0 0
0 comments

(Top Pick Oct 30/13, Up 34.92%) This is a spin off from Pfizer and focused on animals.  Sales are growing at 3 times industry average because they dominate in market share.  1 of 3 FDA approved drugs are theirs.  They are looking to increase their operating efficiencies.

Consumer Products
0 0 0 0 0
0 comments
Mohsin Bashir

VP Investm, Stone Asset Manageme...

Price Price
$43.240
Owned Owned
Yes

TOP PICK
Zoetis Inc(ZTS-N) 

October 30, 2013

Largest animal healthcare company globally. There are opportunities with their ability to increase their animal companion ability where there is an increasing amount of emerging markets moving to a higher standard of living and higher adoption of companion animals. 0.81% dividend is paltry, but over the course of time he believes this can grow substantially. This has to do with their ability to double their free cash flow of $500 million to over $1 billion inside of 3 years. His target is $37 for 12 months.

Consumer Products
0 0 0 0 0
0 comments

Largest animal healthcare company globally. There are opportunities with their ability to increase their animal companion ability where there is an increasing amount of emerging markets moving to a higher standard of living and higher adoption of companion animals. 0.81% dividend is paltry, but over the course of time he believes this can grow substantially. This has to do with their ability to double their free cash flow of $500 million to over $1 billion inside of 3 years. His target is $37 for 12 months.

Consumer Products
0 0 0 0 0
0 comments
Mohsin Bashir

VP Investm, Stone Asset Manageme...

Price Price
$32.060
Owned Owned
Yes

COMMENT
Zoetis Inc(ZTS-N) 

June 11, 2013

(Pfizer (PFE-N) offered to exchange shares for Zoetis (ZTS-N). What do you think? This is Pfizer’s animal nutrition business and they have been streamlining themselves and focusing on their core pharmaceuticals which is probably a positive for them. Doesn’t know too much about this company.

Consumer Products
0 0 0 0 0
0 comments

(Pfizer (PFE-N) offered to exchange shares for Zoetis (ZTS-N). What do you think? This is Pfizer’s animal nutrition business and they have been streamlining themselves and focusing on their core pharmaceuticals which is probably a positive for them. Doesn’t know too much about this company.

Consumer Products
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$31.700
Owned Owned
No

Showing 1 to 9 of 9 entries
Successfully Saved Company
Successfully Saved Company